UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Clinical cancer research, 2018-04, Vol.24 (8), p.1845-1852

2018

Volltextzugriff (PDF)

Information needs and research priorities in long‐term survivorship of breast cancer: Patients and health professionals' perspectives

European journal of cancer care, 2022-11, Vol.31 (6), p.e13730-n/a

2022

Volltextzugriff (PDF)

Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

PloS one, 2015-01, Vol.10 (1), p.e0116527-e0116527

2015

Volltextzugriff (PDF)

Cross-cultural adaptation, reliability and validity of the Spanish version of the long-term quality of life questionnaire

Frontiers in oncology, 2024-03, Vol.14, p.1375125-1375125

2024

Volltextzugriff (PDF)

2022-RA-1689-ESGO Should immunotherapy be included as first-line adjuvant treatment in high-risk vulvar melanomas?

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A451-A452

2022

Volltextzugriff (PDF)

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1584-1593

2016

Volltextzugriff (PDF)

Hypoglycemic Coma Secondary to Big Insulin‐like Growth Factor II Secretion by a Giant Phyllodes Tumor of the Breast

The breast journal, 2007-03, Vol.13 (2), p.189-191

2007

Volltextzugriff (PDF)

Abstract PS4-12: Potential value of FOXA1 expression as genomic predictor of response to docetaxel and carboplatin neoadjuvant (NA) chemotherapy in patients with triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS4-12-PS4-12

2021

Volltextzugriff (PDF)

A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial—A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS5610-TPS5610

2018

Volltextzugriff (PDF)

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)

The oncologist (Dayton, Ohio), 2019-11, Vol.24 (11), p.e1115-e1122

2019

Volltextzugriff (PDF)

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

European journal of endocrinology, 2017-10, Vol.177 (4), p.309

2017

Volltextzugriff (PDF)

Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone

Hematological oncology, 2014-09, Vol.32 (3), p.139-144

2014

Volltextzugriff (PDF)

Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma

Clinical & translational oncology, 2009-09, Vol.11 (9), p.604-608

2009

Volltextzugriff (PDF)

Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer

Journal of cancer research and clinical oncology, 2006-05, Vol.132 (5), p.332-338

2006

Volltextzugriff (PDF)

Tailored treatment with targeted therapies in non-small cell lung cancer (NSCLC) based on the epidermal growth factor receptor gene ( EGFR ) mutation testing

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e19150-e19150

2014

Volltextzugriff (PDF)

Soft tissue sarcomas: A challenge for oncology

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e21512-e21512

2014

Volltextzugriff (PDF)

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Future science OA, 2019-02, Vol.5 (2), p.FSO370-FSO370

2019

Volltextzugriff (PDF)

Predictive serum biomarkers in metastatic colorectal cancer (mCRC) patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (BVZ) (GEMCAD 09-01)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e14647-e14647

2015

Volltextzugriff (PDF)

Some unusual paraneoplastic syndromes. Case 1. Metastatic squamous cell esophageal cancer to the thumb

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2620-2620

2003

Volltextzugriff (PDF)

Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5549-5549

2021

Volltextzugriff (PDF)

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6027-6027

2014

Volltextzugriff (PDF)

Lumbar region intra-spinal primitive neuroectodermal tumour (PNET) combined with neurofibromatosis type 1

Clinical & translational oncology, 2005-11, Vol.7 (10), p.464-467

2005

Volltextzugriff (PDF)

False Elevation of Serum CA 15-3 Levels in Patients Under Follow-Up for Breast Cancer

The breast journal, 2004-07, Vol.10 (4), p.375-376

2004

Volltextzugriff (PDF)

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

Oncology research and treatment, 2018-01, Vol.41 (12), p.755-761

2018

Volltextzugriff (PDF)

Predictive factors of long-term colorectal cancer survival after ultrasound-controlled ablation of hepatic metastases

Medicina clinica, 2017-04, Vol.148 (8), p.345-350

2017

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(65)
Berichte
(3)

Sprache

Japanisch
(2)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Humans
(28)
Middle Aged
(19)
Female
(18)
Oncology
(18)
Aged
(14)
Male
(14)
Adult
(12)
Retrospective Studies
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Treatment Outcome
(9)
Breast Cancer
(8)
Aged, 80 And Over
(7)
Chemotherapy
(7)
Heart Failure
(7)
Patients
(6)
Analysis
(5)
Inflammation
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Information needs and research priorities in long‐term survivorship of breast cancer: Patients and health professionals' perspectives

Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

Cross-cultural adaptation, reliability and validity of the Spanish version of the long-term quality of life questionnaire

2022-RA-1689-ESGO Should immunotherapy be included as first-line adjuvant treatment in high-risk vulvar melanomas?

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

Hypoglycemic Coma Secondary to Big Insulin‐like Growth Factor II Secretion by a Giant Phyllodes Tumor of the Breast

Abstract PS4-12: Potential value of FOXA1 expression as genomic predictor of response to docetaxel and carboplatin neoadjuvant (NA) chemotherapy in patients with triple negative breast cancer (TNBC)

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone

Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma

Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer

Tailored treatment with targeted therapies in non-small cell lung cancer (NSCLC) based on the epidermal growth factor receptor gene ( EGFR ) mutation testing

Soft tissue sarcomas: A challenge for oncology

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Predictive serum biomarkers in metastatic colorectal cancer (mCRC) patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (BVZ) (GEMCAD 09-01)

Some unusual paraneoplastic syndromes. Case 1. Metastatic squamous cell esophageal cancer to the thumb

Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601)

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Lumbar region intra-spinal primitive neuroectodermal tumour (PNET) combined with neurofibromatosis type 1

False Elevation of Serum CA 15-3 Levels in Patients Under Follow-Up for Breast Cancer

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

Predictive factors of long-term colorectal cancer survival after ultrasound-controlled ablation of hepatic metastases

Aktive Filter

Suchergebnisse filtern